Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction Journal Article
| Authors: | Ku, G. Y.; Ilson, D. H. |
| Article Title: | Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction |
| Abstract: | This review examines the role of combined-modality therapy in the treatment of locally advanced esophageal cancer. While surgery remains a cornerstone of treatment, recent studies have demonstrated that pre- or perioperative chemotherapy is associated with improved survival. Primary chemoradiotherapy is the accepted standard of care for medically inoperable patients. Neoadjuvant chemoradiotherapy continues to be investigated and is associated with several advantages over neoadjuvant chemotherapy alone, including an improvement in the pathologic complete response rate and resectability; patients who achieve a pathologic complete response also appear to have improved survival. Adjuvant chemoradiotherapy may be considered for patients who undergo primity resection of lower esophageal/gastroesophageal junction adenocarcinoma. Future directions include the investigation of novel chemotherapy regimens, the addition of targeted therapies and the use of PET to provide an early assessment of response. © 2008 Expert Reviews Ltd. |
| Keywords: | cancer survival; cancer surgery; overall survival; clinical trial; drug tolerability; review; postoperative period; squamous cell carcinoma; bevacizumab; cisplatin; fluorouracil; drug efficacy; multimodality cancer therapy; drug targeting; capecitabine; paclitaxel; adjuvant therapy; disease free survival; radiation dose; combined modality therapy; chemotherapy; outcome assessment; positron emission tomography; antineoplastic agent; carboplatin; multiple cycle treatment; bone marrow suppression; etoposide; blood toxicity; esophagitis; mucosa inflammation; nausea; continuous infusion; pathology; excision repair cross complementing protein 1; vinblastine; docetaxel; irinotecan; gastrointestinal toxicity; preoperative period; folinic acid; adjuvant chemotherapy; fluorodeoxyglucose f 18; bleomycin; esophagus resection; intermethod comparison; stomach cancer; epirubicin; thymidylate synthase; esophagus cancer; esophageal adenocarcinoma; chemoradiation; esophagus tumor; esophageal neoplasms; neoadjuvant; esophageal cancer; lower esophagus sphincter; esophagogastric junction; adjuvant; multidrug resistance protein 1; 5,10 methylenetetrahydrofolate reductase (fadh2); chemoradiotheraphy; caldesmon; lower esophagus sphincter cancer |
| Journal Title: | Expert Review of Anticancer Therapy |
| Volume: | 8 |
| Issue: | 12 |
| ISSN: | 1473-7140 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2008-12-01 |
| Start Page: | 1953 |
| End Page: | 1964 |
| Language: | English |
| DOI: | 10.1586/14737140.8.12.1953 |
| PUBMED: | 19046115 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 17 November 2011" - "CODEN: ERATB" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work